INTENSITY THERAPEUTICS INC (INTS) Stock News

USA - NASDAQ:INTS - US45828J1034 - Common Stock

0.2468 USD

-0.01 (-5%)

Last: 9/23/2025, 8:00:02 PM

0.2517 USD

+0 (+1.99%)

After Hours: 9/23/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

INTS Latest News, Press Relases and Analysis

All

Press Releases

14 days ago - By: Benzinga - Mentions: ACTU CAMP ONC REVB ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

14 days ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update

22 days ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

a month ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement

2 months ago - By: The Motley Fool

Intensity (INTS) Q2 Net Loss Drops 50%

2 months ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

2 months ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025

3 months ago - By: Benzinga - Mentions: IGC AEMD MREO RARE ...

12 Health Care Stocks Moving In Wednesday's After-Market Session

3 months ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics, Inc. Announces Pricing of Public Offering

3 months ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

3 months ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study

4 months ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

4 months ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon

4 months ago - By: Intensity Therapeutics Inc.

Intensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update